Tecan focuses on long-term strategy, shares in a robust life-science peer field

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-23, 21:01.

Tecan Group AG (CH0012100191) positions itself as a specialist for laboratory automation and diagnostics with a clear long-term strategy, while its shares trade on the SIX Swiss Exchange alongside peers such as Roche and Straumann in the Swiss life-science cluster.

Strategic position in lab automation

Tecan focuses on automated liquid handling platforms, sample preparation and integrated workflow solutions that address pharmaceutical research, clinical diagnostics and applied markets like food safety testing, forming the technological backbone in many automated laboratories worldwide. Company product overview

The company pursues a dual business model, combining an own-branded instruments and consumables portfolio with OEM solutions that it develops and manufactures for diagnostics and life-science partners, aiming to capture both recurring revenue and long-term platform placements with industrial customers. OEM business description

Long-term growth drivers and sector peers

Structural drivers for Tecan include rising throughput requirements in pharmaceutical R&D, the expansion of high-throughput screening in biotech, and the global trend toward automated and standardized diagnostic workflows, which underpin demand for liquid handlers and microplate readers over multi-year investment cycles. Reuters analysis of lab automation trends

In the international life-science tools universe, Tecan competes with larger players such as Thermo Fisher Scientific and Danaher’s Beckman Coulter in automation, while in Switzerland it shares investor attention on SIX with diagnostics and medtech names like Roche and Straumann that also benefit from growing healthcare expenditure and research intensity. Financial Times sector overview

The product behind the stock

A representative example of Tecan’s portfolio is the Infinite microplate reader line, which provides absorbance, fluorescence and luminescence detection for applications such as cell-based assays, ELISA workflows and nucleic acid quantification in research and diagnostics laboratories. Infinite series product page

Where the stock trades today

The Tecan shares (CH0012100191) last closed on the SIX Swiss Exchange at 162.40 Swiss francs on 2026-06-22, 22:44.

This article is for informational purposes only and does not constitute investment advice, an offer or solicitation to buy or sell any securities. Historical performance is not a reliable indicator of future results.